The studies on the mechanism of pharmacokinetic interaction of aluminum hydroxide with new quinolones, ofloxacin, enoxacin and norfloxacin, were performed in rats. New quinolones (20 mg/kg) were administered orally with or without aluminum hydroxide or aluminum chloride (50 mg/kg). Co-administration of alumi num hydroxide induced a significant decrease in C.ax of enoxacin and norfloxacin , and in the AUC values of the three drugs. This effect was enhanced by co-admini stration of aluminum chloride. The combination of aluminum hydroxide caused a significant increase in the intestinal contents and decrease in urinary excretion of new quinolones. The formation of the stable chelate of new quinolones with All+ ions formed from aluminum hydroxide in the same acidic solution as gastric juice was observed. Thus, it is concluded that the co-administration of aluminum hydro xide affects the pharmacokinetics of new quinolones, probably, by the inhibition of the intestinal absorption of new quinolones by the chelate formation of these compounds with All+ ions released from aluminum hydroxide in the gastric juice.
Introduction
The introduction of new quinolones to the chemotherapy of patients with various infec tious diseases has brought out not only their outstanding chemotherapeutic effectiveness against the diseases, but also undesirable adverse reactions of the drugs. A major adverse reactions of new quinolones have shown to be gastrointestinal symptoms including nausea and vomiting (1) . In order to suppress these symptoms, aluminum or magnesium-containing antacids have been used frequently by the concomitant administration. However, it has been demonstrated recently that the co-administration of the antacids, including aluminum hydroxide, affects adversely the oral absorbability of various new quinolones in human subjects (2) (3) (4) (5) (6) (7) (8) . Although many investigators have suggested the chelate formation of new quinolones with metal ions in the gastrointestinal tract as the mechanism of the inhibition of absorption of the drugs, details of the pharmacokinetic interaction of the antacids with new quinolones remain unknown so far. Therefore, mechanistic studies on pharmacokinetic interaction of aluminum hydroxide with new quinolones were carried out.
This paper describes the results on the effect of concurrent administration of aluminum hydroxide or aluminum chloride on the pharmacokinetics of ofloxacin, enoxacin and norflo xacin in rats, and on the formation of chelates of new quinolones with various metal ions.
Experimental

Drugs and Reagents
Ofloxacin (Daiichi Seiyaku Co., Ltd., Tokyo, Japan), enoxacin (Dainippon Pharmaceu tical Co., Ltd., Osaka, Japan), norfloxacin (Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan), and aluminum hydroxide (Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) were used in this study. 
Results
Effect of Combination of Aluminum hydroxide or Aluminum chloride on Serum
Concentrations of New Quinolones
As shown in Fig. 1 , serum concentrations of ofloxacin, enoxacin and norfloxacin were decreased significantly up to 2 hours after dosing together with aluminum hydroxide. This combination effect on the serum concentrations of ofloxacin was more pronounced by the concurrent administration of aluminum chloride instead of aluminum hydroxide. Table I shows the results on the effect of combination of aluminum hydroxide or alu minum chloride on the pharmacokinetic parameters of ofloxacin, enoxacin and norfloxacin.
Concurrent administration of aluminum hydroxide induced a significant decrease in Cmax of enoxacin and norfloxacin, and a significant decrease in AUC values of these three drugs.
Co-administration of aluminum chloride caused a significant decrease in Cm.., a significant prolongation of Tmax, and a significant increase in AUC of ofloxacin. This combination effect of aluminum chloride on the pharmacokinetic parameters of ofloxacin was much larger than that of aluminum hydroxide. Each value represents the mean±standard error for 3 rats. The fasted animals received an oral dose of new quinolones (20 mg/kg) with or without aluminum hydroxide (50 mg/kg). * P<0.05 and ** P<0.01 vs. new quinolones alone.
Effect of Combination of Aluminum hydroxide on the Urinary Excretion of New
Quinolones As presented in Table II , the co-administration with aluminum hydroxide produced a significant decrease in the urinary excretion of ofloxacin and enoxacin over a period of 8-24
hours after administration. Urinary excretion of norfloxacin was reduced significantly by the concurrent administration of aluminum hydroxide throughout the experimental period.
Formation of Stable Chelates of New Quinolones with Aluminum Ions
As shown in Fig. 3 , aluminum ions were formed, in approximately 10 %, from aluminum hydroxide suspended at the concentration of 10 mg/ml in almost the same acidic solution (pH 1. 0) as the rat gastric juice. 
Discussion
In the present study, it has been demonstrated that the co-administration with aluminum hydroxide induces a significant decrease in the rat serum concentrations of new quinolones which results in a significant decrease in their Cmax and AUC, and a significant decrease in the urinary excretion of new quinolones due to the inhibition of intestinal absorption of the drugs. In addition, this combination effect has been shown to be enhanced by the concurrent administration with aluminum chloride instead of aluminum hydroxide, thus suggesting that
All' ions play a major role in the inhibition of intestinal absorption of new quinolones. It has been reported that All' ions reduce Cmax and prolong the time to reach Cmax (Tmax) without affecting AUC by delaying the gastric emptying of the concomitant drugs (13) (14) (15) . However, the interaction of new quinolones with aluminum hydroxide is not the case, because the present results have shown that the combination of aluminum hydroxide does not affect the gastric emptying of ofloxacin. It is considered that the insufficient amount of aluminum ion to delay the gastric emptying rate is produced in the stomach after an oral administration of aluminum hydroxide.
Thus, it is concluded that the pharmacokinetic interaction of aluminum hydroxide with new quinolones may be caused by the inhibition of the intestinal absorption of these drugs due to the stable chelate formation of the drugs with All' ions released from aluminum hydroxide in the gastric juice.
